Semaglutide reduces COVID-19 related deaths in patients with obesity and CVD
Semaglutide reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established...
top of page
Browse by category
Search
European Society of Cardiology Obesity Consensus Statement
The European Society of Cardiology (ESC) Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC...
Browse by tag
bottom of page